Stock listing
OTC:IPIX Innovation Pharmaceuticals Inc. Stock
Follow Innovation Pharmaceuticals Inc. into a list and get an email when it puts out news.
Share price · OTC:IPIX
$0.0002 USD 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.0002 – $0.0002 USDNov 20, 2026
- Volume
- 32,842 sharesNov 20, 2026
- Market cap
- $102,803 USDAt the close on Nov 20, 2026 · price × 514.0M shares outstanding
- 52-week range
- $0.0001 – $0.0500 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $133 USDMedian day 63,438 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:IPIX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 32,842 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 14,833 | |
| $0.0002 | -0.0003 | -60.0% | $0.0005 | $0.0010 | $0.0002 | 483,570 | |
| $0.0005 | +0.0003 | +150.0% | $0.0002 | $0.0006 | $0.0002 | 214,380 | |
| $0.0002 | -0.0003 | -60.0% | $0.0005 | $0.0014 | $0.0002 | 454,641 | |
| $0.0005 | +0.0003 | +150.0% | $0.0005 | $0.0005 | $0.0005 | 18,000 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 6,180 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 34,386 | |
| $0.0002 | -0.0003 | -60.0% | $0.0002 | $0.0002 | $0.0002 | 47,503 | |
| $0.0005 | -0.0003 | -37.5% | $0.0001 | $0.0010 | $0.0001 | 657,142 | |
| $0.0008 | +0.0006 | +300.0% | $0.0010 | $0.0018 | $0.0001 | 90,127 | |
| $0.0002 | 0.0000 | 0.0% | $0.0010 | $0.0010 | $0.0002 | 153,400 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0016 | $0.0002 | 442,333 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 3,226 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 1,000 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 2,500 | |
| $0.0002 | -0.0008 | -80.0% | $0.0002 | $0.0002 | $0.0002 | 125,000 | |
| $0.0010 | +0.0003 | +42.9% | $0.0009 | $0.0010 | $0.0002 | 1,505,425 | |
| $0.0007 | +0.0001 | +16.7% | $0.0007 | $0.0007 | $0.0007 | 133,500 | |
| $0.0006 | +0.0001 | +20.0% | $0.0006 | $0.0006 | $0.0005 | 1,082,895 | |
| $0.0005 | +0.0002 | +66.7% | $0.0001 | $0.0005 | $0.0001 | 1,093,979 | |
| $0.0003 | +0.0001 | +50.0% | $0.0002 | $0.0003 | $0.0002 | 74,582 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 122,691 | |
| $0.0002 | 0.0000 | 0.0% | $0.0001 | $0.0002 | $0.0001 | 114,800 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 150,000 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0018 | $0.0002 | 69,425 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 7,500 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 8,932 | |
| $0.0002 | -0.0003 | -60.0% | $0.0010 | $0.0020 | $0.0002 | 75,311 | |
| $0.0005 | +0.0003 | +150.0% | $0.0002 | $0.0005 | $0.0002 | 194,161 | |
| $0.0002 | 0.0000 | 0.0% | $0.0015 | $0.0020 | $0.0002 | 108,000 | |
| $0.0002 | +0.0001 | +100.0% | $0.0001 | $0.0020 | $0.0001 | 231,810 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 3,700 | |
| $0.0001 | -0.0001 | -50.0% | $0.0001 | $0.0001 | $0.0001 | 57,451 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 25,200 | |
| $0.0002 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0002 | 1,100 | |
| $0.0002 | -0.0008 | -80.0% | $0.0002 | $0.0002 | $0.0002 | 140 | |
| $0.0010 | +0.0007 | +233.3% | $0.0010 | $0.0010 | $0.0010 | 284,981 | |
| $0.0003 | 0.0000 | 0.0% | $0.0024 | $0.0024 | $0.0003 | 416,100 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 17,918 | |
| $0.0003 | 0.0000 | 0.0% | $0.0026 | $0.0026 | $0.0003 | 46,769 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 57,304 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 210 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 1,000 | |
| $0.0003 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0003 | 600,100 | |
| $0.0003 | 0.0000 | 0.0% | $0.0001 | $0.0003 | $0.0001 | 23,030 | |
| $0.0003 | -0.0017 | -85.0% | $0.0026 | $0.0026 | $0.0003 | 805,100 | |
| $0.0020 | +0.0012 | +150.0% | $0.0003 | $0.0020 | $0.0003 | 290,000 | |
| $0.0008 | -0.0007 | -46.7% | $0.0001 | $0.0030 | $0.0001 | 46,411 | |
| $0.0015 | 0.0000 | 0.0% | $0.0015 | $0.0028 | $0.0015 | 52,327 | |
| $0.0015 | +0.0011 | +275.0% | $0.0004 | $0.0030 | $0.0004 | 1,094,860 | |
| $0.0004 | -0.0002 | -33.3% | $0.0004 | $0.0007 | $0.0004 | 19,780 | |
| $0.0006 | +0.0002 | +50.0% | $0.0006 | $0.0006 | $0.0004 | 12,300 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 10,075 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 13,000 | |
| $0.0004 | -0.0001 | -20.0% | $0.0026 | $0.0026 | $0.0004 | 541,632 |
- Ticker
- OTC:IPIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Latest news
Innovation Pharmaceuticals Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 192 in all · newest Apr 17, 2023 · oldest 2016
- Decks
- 3 decks · latest September 2022
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Innovation Pharmaceuticals Inc. · OTC:IPIX | US$102,803 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.51 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,477 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| Median of the others | US$192,289 | US$73,510 | 1.2× | 18.5× | 0.2× | −382.1% | 0.0× | 1.14 |
Team and board
Officers
| Officer | Role |
|---|---|
| Leo Ehrlich | Chief Executive Officer, Chief Financial Officer; Board Chairman |
| Jane Harness | Senior Vice President, Clinical Sciences and Portfolio Management |
Board
| Director | Role |
|---|---|
| Leo Ehrlich | Chief Executive Officer, Chief Financial Officer; Board Chairman |
| Barry Schechter | Independent Board Member |
| Zorik Spektor | Independent Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Nov 20, 2023 · After close | −16.7% |
| Q4 2023 | Sep 28, 2023 · Before open | 0.0% |
| Q3 2023 | May 15, 2023 · Before open | 0.0% |
| Q2 2023 | Feb 15, 2023 · After close | 0.0% |
| Q1 2023 | Nov 10, 2022 · After close | 0.0% |
| Q4 2022 | Sep 28, 2022 · After close | 0.0% |
| Q3 2022 | May 13, 2022 · After close | 0.0% |
| Q2 2022 | Feb 14, 2022 · After close | 0.0% |
| Q1 2022 | Nov 9, 2021 · After close | −10.8% |
| Q4 2021 | Sep 27, 2021 · After close | 0.0% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2021 | May 13, 2021 · Before open | +5.6% |
| Q2 2021 | Feb 22, 2021 · After close | −5.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2022) | Investor deck | 14 slides | September 2022 |
| Medical Dermatology Therapeutic R&D and Technical Innovation Workshop 2016 | Conference | 16 slides | Nov 30, 2017 |
| Technical Presentation (July 2017) | Technical | 23 slides | Jul 13, 2017 |
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.0K | 18.0K | 23.0K | 423.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 373.0K | 382.0K | 378.0K | 371.0K | 413.0K | 406.0K | 420.0K | 0 | 0 | |
| Gross profit | -373.0K | 18.0K | -378.0K | 423.0K | -371.0K | -413.0K | -406.0K | -420.0K | 0 | 0 |
| Research and development | 1.46M | 4.81M | 6.64M | 2.79M | 4.34M | 11.4M | 12.8M | 8.95M | 10.5M | 6.34M |
| Selling, general and administrative | 995.0K | 1.96M | 2.00M | 2.27M | 2.11M | 2.58M | 2.55M | 3.05M | 2.42M | 1.69M |
| Operating income | -172.0K | -6.92M | -9.02M | -4.63M | -6.45M | -13.9M | -15.3M | -12.7M | -13.0M | -8.04M |
| Depreciation and amortization | 373.0K | 382.0K | 378.0K | 373.0K | 371.0K | 413.0K | 405.0K | 420.0K | 404.0K | 289.0K |
| EBITDA | 201.0K | -6.54M | -8.64M | -4.26M | -6.08M | -13.5M | -14.9M | -12.2M | -12.6M | -7.75M |
| Interest expense | 28.0K | 115.0K | 4.86M | 260.0K | 2.20M | 202.0K | 202.0K | 202.0K | 202.0K | 210.0K |
| Income before tax | -3.17M | -7.04M | -13.9M | -6.65M | -8.68M | -16.4M | -15.5M | -12.9M | -13.1M | -8.25M |
| Income tax | 172.0K | 120.0K | 4.86M | 362.0K | 390.0K | -2.22M | 198.0K | 202.0K | 202.0K | 1.00K |
| Net income | -3.17M | -7.04M | -13.9M | -6.65M | -9.07M | -16.4M | -15.5M | -12.9M | -13.1M | -8.25M |
| Earnings per share, basic | -0.01 | -0.01 | -0.04 | -0.03 | -0.05 | -0.11 | -0.12 | -0.11 | -0.11 | -0.08 |
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.52M | 3.81M | 10.2M | 6.02M | 579.0K | 2.42M | 4.14M | 6.31M | 8.41M | 4.99M |
| Short-term investments | 78.0K | |||||||||
| Receivables | 29.0K | 26.0K | 26.0K | 12.0K | ||||||
| Inventory | 49.0K | -26.0K | -26.0K | -12.0K | ||||||
| Current assets | 1.63M | 3.95M | 10.7M | 6.11M | 625.0K | 2.60M | 4.47M | 6.69M | 8.77M | 5.56M |
| Property, plant and equipment | 1.00K | 2.00K | 120.0K | 90.0K | 38.0K | 39.0K | ||||
| Total assets | 7.52M | 10.4M | 14.3M | 9.25M | 4.05M | 6.54M | 9.11M | 11.4M | 14.3M | 10.9M |
| Accounts payable | 1.50M | 1.08M | 1.08M | 557.0K | 641.0K | 1.68M | 105.0K | 57.0K | 1.84M | 43.0K |
| Current liabilities | 5.02M | 4.81M | 6.54M | 7.37M | 7.30M | 8.69M | 10.6M | 8.48M | 7.29M | 9.65M |
| Long-term debt | 879.0K | |||||||||
| Total debt | 725.0K | 1.29M | 1.87M | 2.46M | 1.92M | 2.02M | 2.02M | 2.02M | 2.02M | 2.02M |
| Total liabilities | 5.48M | 5.65M | 6.79M | 7.79M | 8.18M | 8.69M | 10.6M | 8.48M | 7.29M | 9.65M |
| Shareholders' equity | 2.04M | 4.73M | 7.51M | 1.46M | -4.13M | -2.15M | -1.46M | 2.96M | 7.02M | 1.21M |
| Shares outstanding | 505.8M | 503.9M | 386.2M | 237.3M | 178.2M | 144.5M | 127.3M | 119.9M | 115.1M | 105.0M |
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.11M | -6.28M | -9.49M | -4.16M | -6.33M | -13.3M | -11.7M | -9.89M | -13.1M | -7.51M |
| Capital spending | -60.0K | -80.0K | -72.0K | -91.0K | -86.0K | -117.0K | -336.0K | -414.0K | -459.0K | -2.67M |
| Free cash flow | -2.17M | -6.36M | -9.57M | -4.25M | -6.42M | -13.4M | -12.0M | -10.3M | -13.5M | -10.2M |
| Cash from investing | -60.0K | -4.08M | -72.0K | -91.0K | -46.0K | -104.0K | -336.0K | -414.0K | -459.0K | -2.65M |
| Cash from financing | -123.0K | 3.97M | 13.7M | 9.69M | 4.53M | 11.7M | 9.88M | 8.20M | 17.0M | 12.2M |
| Dividends paid | -86.0K | -86.0K | -86.0K | -9.82M | -4.62M | |||||
| Share buybacks | 0 | -670.0K | -55.0K | -91.0K | -172.0K | -220.0K | 8.20M | 17.0M | 12.5M | |
| Change in cash | -2.29M | -6.39M | 4.18M | 5.44M | -1.84M | -1.72M | -2.17M | -2.10M | 3.42M | 2.03M |
Cap table
Built by 6ix from Innovation Pharmaceuticals Inc.’s releases
- Common shares
- 514,013,755
- Fully diluted
- 514,013,755
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 514,013,755 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 514,013,755 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Arthur Peter Bertolino Other companies: Cellceutix Corp (Pres. & Chief Medical Officer · Jun 30, 2016 – Jun 30, 2016 · Past); Revance Therapeutics, Inc. (EVP and Chief Medical Officer · Sep 2, 2014 – Nov 17, 2015 · Past) | President and CMO, Director · Jun 30, 2017 – Sep 1, 2019 · Past |
| Barry SchecHter Other companies: Cellceutix Corp (Director · Jun 10, 2016 – Jul 7, 2016 · Past) | Independent Board Member · Since at least Sep 28, 2022 |
| Leo Ehrlich Other companies: Cellceutix Corp (Chief Executive Officer, Director · Jul 30, 2012 – Dec 30, 2014 · Past) | Chief Executive Officer, Chief Financial Officer; Board Chairman · Since at least Jun 30, 2017 |
| Zorik Spektor Other companies: Cellceutix Corp (Director · Jun 10, 2016 – Jul 11, 2016 · Past) | Independent Board Member · Since at least Sep 28, 2022 |
| Jane Harness | Senior Vice President, Clinical Sciences and Portfolio Management · Since at least Aug 30, 2016 |
Log in to ask 6ix AI your own questions about Innovation Pharmaceuticals Inc.